Latest Headlines

Latest Headlines

Bind shares slide after Amgen walks out of $180M collaboration deal

Amgen has bowed out of a $180 million collaboration with Cambridge, MA-based Bind Therapeutics, ending work on a new therapy for solid tumors by amping up an Amgen drug with the biotech's nanoengineering technology. News of the research setback--which ends the first big pact inked for the biotech's delivery tech--took a bite out of Bind's shares, sending its stock down by more than 10%.

Sanofi, CureVac extend vax partnership with new $205M-plus mRNA pact

Sanofi Pasteur and Germany's CureVac first joined up in 2011 with a licensing option agreement for a slew of pathogens. Now, they're beefing up their partnership with another licensing deal, this one giving the French company rights to a new mRNA-based vaccine.

Recipharm and CTC unite for early-stage trials

Contract developer Recipharm and CTC Clinical Trial Consultants are joining forces to offer combined Phase I services, pooling their capabilities in manufacturing and trial conduction.

Evotec pockets a payment in its Boehringer partnership

German contractor Evotec has notched another milestone in its years-long arrangement with Boehringer Ingelheim, netting €1 million ($1.4 million) after moving a respiratory compound into preclinical study.

ClinicalRM teams up with an Ohio network for clinical trials

CRO ClinicalRM has signed a deal with the Ohio Clinical Trials Collaborative to join forces in a co-marketing arrangement, looking to expand its role in the state's drug and device development scene.

Bristol-Myers enlists Duke's CRO to help it share trial data

Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.

Covance is creating an OkCupid for molecules

As last week's BIO conference well illustrated, biotech companies go to great lengths to flaunt their assets in front of potential partners from Big Pharma. Global CRO Covance is developing a system it believes can make that process more efficient: an online platform that allows drug developers to securely list their up-for-license molecules for would-be collaborators.

Pfizer to partner with South African university on preclinical research

The partnership may include the use of Pfizer's genetically modified animal models to evaluate the safety and efficacy of therapeutic molecules in oncology, inflammation, immunology, central nervous system and cardiovascular system disorders.

Mersana grabs a $792M ADC development pact with Merck KGaA

Mersana Therapeutics has inked another antibody-drug conjugate development pact, this time with the R&D team at Merck KGaA in Germany.

Merck targets Alzheimer's in $526M collaboration on new cognitive treatment

Last summer, Bionomics struck a $172 million discovery deal on new pain meds with Merck. And now the pharma giant has come back to the bargaining table to bag a much bigger collaboration with the Adelaide, Australia-based biotech, paying $20 million upfront and promising up to $506 million in milestones to collaborate on a new Alzheimer's drug.